AC 45594 |
| Catalog No.GC10908 |
inverse agonist of steroidogenic factor 1 (SF-1)
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 13037-86-0
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
AC 45594 is a full inverse agonist of steroidogenic factor 1 (SF-1) with an IC50 value of 50~100 nM [1].
SF-1 is a constitutively nuclear hormone receptor. It is essential to the development of gonadal and adrenal glands. It acts as a shaping factor in sexual differentiation and determination. Its effects are exerted primarily via controlling steroid hormone synthesis [1].
Human adrenocortical H295R/TR SF-1 cells were overexpressing SF-1 in a Dox-inducible fashion. After a 4-day treatment with AC 45594, the proliferation of H295R/TR SF-1 cells cultured in basal conditions was inhibited in a dose-dependent manner. AC 45594 showed maximal effect at 10 µM. SF-1 overexpression induced cell proliferation. In the presence of Dox, incubation with AC 45594 at 1 µM markedly reduced the effect of SF-1 overexpression. Moreover, treatment with AC 45594 increased the percentage of sub-G1 (apoptotic) cells [2]. In human adrenocortical H295 cells, cAMP is able to induce the expression of StAR. This induction is dependent on the presence of SF-1. Incubation with AC 45594 dose-dependently reduced amounts of the StAR mRNA to basal levels. At the protein level, 24 h after the cAMP treatment, StAR was increased by 30-fold. But treatment with AC 45594 completely and dose-dependently reversed the cAMP-dependent activation of StAR [1].
No result regarding the effect of AC 45594 in animal bodies had been found.
References:
[1]. Del Tredici AL, Andersen CB, Currier EA, et al. Identification of the first synthetic steroidogenic factor 1 inverse agonists: pharmacological modulation of steroidogenic enzymes. Molecular pharmacology, 2008, 73(3): 900-908.
[2]. Doghman M, Cazareth J, Douguet D, et al. Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists. The Journal of Clinical Endocrinology & Metabolism, 2009, 94(6): 2178-2183.
| Cas No. | 13037-86-0 | SDF | |
| Chemical Name | 4-(heptyloxy)phenol | ||
| Canonical SMILES | OC1=CC=C(C=C1)OCCCCCCC | ||
| Formula | C13H20O2 | M.Wt | 208.3 |
| Solubility | <20.83mg/ml in DMSO; <20.83mg/ml in ethanol | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.8008 mL | 24.0038 mL | 48.0077 mL |
| 5 mM | 0.9602 mL | 4.8008 mL | 9.6015 mL |
| 10 mM | 0.4801 mL | 2.4004 mL | 4.8008 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 23 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *